HomeCompareMVRBF vs MRK

MVRBF vs MRK: Dividend Comparison 2026

MVRBF yields 243.90% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MVRBF wins by $394.56M in total portfolio value
10 years
MVRBF
MVRBF
● Live price
243.90%
Share price
$0.82
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$394.62M
Annual income
$218,439,906.42
Full MVRBF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — MVRBF vs MRK

📍 MVRBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMVRBFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MVRBF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MVRBF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MVRBF
Annual income on $10K today (after 15% tax)
$20,731.71/yr
After 10yr DRIP, annual income (after tax)
$185,673,920.46/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MVRBF beats the other by $185,665,323.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MVRBF + MRK for your $10,000?

MVRBF: 50%MRK: 50%
100% MRK50/50100% MVRBF
Portfolio after 10yr
$197.34M
Annual income
$109,225,010.10/yr
Blended yield
55.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MVRBF
No analyst data
Altman Z
1.7
Piotroski
0/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MVRBF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMVRBFMRK
Forward yield243.90%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$394.62M$57.7K
Annual income after 10y$218,439,906.42$10,113.78
Total dividends collected$375.65M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MVRBF vs MRK ($10,000, DRIP)

YearMVRBF PortfolioMVRBF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$35,090$24,390.24$11,213$373.04+$23.9KMVRBF
2$117,533$79,986.88$12,667$512.06+$104.9KMVRBF
3$376,147$250,386.00$14,439$708.14+$361.7KMVRBF
4$1,151,374$748,897.11$16,640$988.16+$1.13MMVRBF
5$3,374,355$2,142,384.97$19,432$1,394.07+$3.35MMVRBF
6$9,478,533$5,867,972.46$23,057$1,992.90+$9.46MMVRBF
7$25,546,778$15,404,747.63$27,889$2,894.79+$25.52MMVRBF
8$66,138,099$38,803,046.68$34,518$4,286.29+$66.10MMVRBF
9$164,653,072$93,885,306.32$43,912$6,494.35+$164.61MMVRBF
10$394,618,693$218,439,906.42$57,714$10,113.78+$394.56MMVRBF

MVRBF vs MRK: Complete Analysis 2026

MVRBFStock

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Full MVRBF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this MVRBF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MVRBF vs SCHDMVRBF vs JEPIMVRBF vs OMVRBF vs KOMVRBF vs MAINMVRBF vs JNJMVRBF vs ABBVMVRBF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.